Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9533464 | 0.77 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29350415 | 0.74 | — | — | |
| SCHEMBL11831916 | 0.74 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10013987 | 0.72 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19708014 | 0.70 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20924767 | 0.70 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19480772 | 0.70 | — | — | |
| SCHEMBL3853831 | 0.67 | CA1 (0.33) | CA2CA1 | |
| SCHEMBL16501550 | 0.67 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL15091 | 0.65 | CA12 (0.52) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651237-B1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | WANG BING | 2010-08-12 | — | — | US | disclosed |
| EP-1651237-A4 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1651237-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | Galileo Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005016270-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | GALILEO PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | KRT18, CUTA, TUBB1 | CHRM2 3645/4885CHRM4 4225/4885CHRM5 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.